Welcome to our dedicated page for Owlet news (Ticker: OWLT), a resource for investors and traders seeking the latest updates and insights on Owlet stock.
Owlet, Inc. reports business developments for a pediatric health platform built around smart infant monitoring, connected wearables, video monitoring and app-based health insights. Company news commonly covers FDA-cleared pediatric monitoring products, including BabySat, consumer monitoring systems such as Dream Duo, and software services including Owlet360 and pediatric telehealth features.
Recurring updates also include quarterly financial results, guidance, leadership and governance changes, DME distribution partnerships, product recognition, and initiatives tied to Owlet's pediatric health and sleep data platform. These announcements reflect the company's mix of consumer baby monitoring, prescription monitoring access, subscriptions and connected-care services.
Owlet (NYSE: OWLT) will release fourth quarter and full year 2025 results after market close on March 5, 2026. A conference call with CEO Jonathan Harris and CFO Amanda Twede Crawford is set for 4:30 p.m. ET the same day, with webcast access and a replay on the investor site.
Dial-in numbers and an access code are provided for live participation; the webcast will be available in the Events section of the company investor relations website.
Owlet (NYSE: OWLT) announced a strategic partnership with PromptCare to expand DME distribution of its pediatric, FDA-cleared pulse oximeter BabySat.
The collaboration leverages PromptCare’s >40 years in respiratory care and 25+ U.S. locations to access pediatric hospital-to-home pathways, pilot deployments, and expected incremental unit shipments as pilots scale.
Owlet (NYSE: OWLT) announced a strategic partnership with private AI platform webAI to build enterprise-grade, security-first AI on Owlet’s proprietary infant health and sleep dataset.
The collaboration aims to deliver increasingly personalized sleep and health insights, support scalable future products, and keep family data protected while leveraging longitudinal pediatric data.
Owlet (NYSE: OWLT) released its first Annual Baby Sleep Report on January 21, 2026, analyzing data from over 1.2 million babies and nearly 900 million hours of monitored infant sleep in 2025. Key findings: most bedtime changes occur in the first six months; median longest nighttime sleep stretches reach nearly 9 hours by 6–8 months; night wakings drop by more than half by 9 months; largest sleep and pulse changes occur in months 1–2. The report cites Dream Sock as an FDA-cleared wearable and notes insights come from aggregated Owlet users and may not represent all babies.
Owlet (NYSE: OWLT) announced a national durable medical equipment partnership with 1 Natural Way to expand insurance-supported access to its FDA-cleared prescription pulse oximeter, BabySat.
The collaboration lets families nationwide complete a qualification questionnaire and, with a prescription, order BabySat through 1NaturalWay.com using available insurance coverage; 1 Natural Way will manage benefits verification and documentation support. The partnership highlights a focus on Medicaid and TRICARE families (TRICARE covers roughly 9.5 million individuals). Insurance coverage and reimbursement vary by plan and state and are not guaranteed.
Owlet (NYSE: OWLT) launched Owlet360 in the UK and Ireland on December 10, 2025, a subscription service that delivers personalized sleep and health insights for families using Dream Sock, Dream Sight or Owlet Cam 2.
Core live vital monitoring and real-time notifications remain free. Owlet360 leverages a dataset from more than 2.5 million babies and follows rapid U.S. adoption of over 90,000 subscribers. The service is available now with monthly or yearly plans and a seven-day free trial for eligible users.
Owlet (NYSE: OWLT) announced on December 5, 2025 that its Dream Sock has received TGA approval and is now available in Australia and New Zealand via Owlet websites and select retail partners. The launch includes the first international rollout of the Owlet360 subscription, extending the Company’s recurring-revenue platform.
Dream Sock is a clinically validated wearable for infants 0–18 months (2.5–13.6 kg) that tracks pulse rate, oxygen level, and sleep trends with real-time alerts via the Owlet Dream App and Base Station. Owlet360 adds personalized guidance, expert resources, daily sleep reports, and expanded trend analytics above the app’s free core tracking.
Owlet (NYSE: OWLT) was named to Fast Company’s 2025 Brands That Matter list on December 2, 2025, recognizing brands that achieve cultural significance and deep customer connection.
Owlet highlighted its human-centered mission, the first and only FDA-cleared baby monitor, a growing ecosystem of connected products, partnerships with more than 40 global nonprofits, and over $2.5M donated in product and charitable support.
The recognition emphasizes Owlet’s brand storytelling, community engagement, and reach among millions of parents worldwide as it seeks to expand into underserved markets.
Owlet (NYSE: OWLT) selected OpenSynergy's Blue SDK to provide Bluetooth® connectivity for its new Dream Sight camera baby monitor, aiming to improve connection stability, interoperability, and security across iOS and Android devices.
The Blue SDK is pre-qualified with the Bluetooth SIG, which Owlet says streamlined qualification and certification. Owlet highlighted faster development timelines, ongoing security monitoring by OpenSynergy, and broader Bluetooth feature support; Dream Sight is available now alongside Dream Sock and Dream Duo, and Owlet reports being trusted by over 2.5 million families in 30+ countries.
Owlet (NYSE: OWLT) announced a partnership with Locus Health on November 19, 2025 to integrate data from Owlet’s FDA-cleared BabySat prescription device into Locus Health’s remote patient monitoring platform. The integration delivers ongoing, secure access to infant vitals — including oxygen saturation and pulse rate — into clinicians’ existing workflows after hospital discharge.
This collaboration aims to improve continuity of care for infants leaving ICU, reduce manual data entry and transcription errors, and extend monitoring for complex conditions while leveraging Owlet’s scale (over 2.5 million babies monitored).